• Share price
• Investor PDF
• Interims 2008 PDF

30 May 2007

Final Results for the year ended 31 December 2006

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce its final results for the year ended 31 December 2006.

Operational Highlights

• Significant progress across our growing product and IP portfolio
• CSD500 - preparation for launch underway by Durex®-maker SSL International plc ahead of regulatory approval for our condom product to help healthy men maintain a firm erection
• MED2002 - partnering negotiations re-started following the return of development rights for our topical gel for erectile dysfunction
• DermaSys® - launch of brand name for the Group’s unique, topical drug delivery technology
• TPR100 - exclusivity agreement signed with GlaxoSmithKline Consumer Healthcare for the negotiation of global distribution rights for our pain relief product

Financial Highlights

• Net loss of £1.8 million (2005: net loss of £1.9 million)
• Net cash at 31 December 2006 of £3.8 million (2005: £1.8 million)
  

James Barder, Futura’s Chief Executive, said:

“The outlook remains positive for the remainder of the year: interest from potential partners for MED2002 is encouraging, our portfolio of product opportunities is broadening and we are on track to achieve the major milestone of regulatory approval for our most advanced product, CSD500, putting us firmly on course to becoming a business with a recurring royalty income stream.”

The full results are available to download in PDF format.

Site map | Contact us | By using the website, you are deemed to have accepted the terms of the disclaimer.

© and Database Right: Futura Medical Plc 2004 - 2008. All rights reserved.